Phathom Pharmaceuticals, Inc.

NASDAQ:PHAT

Biotechnology

Healthcare
$5.30 -2.45%

-$0.27 today

Market cap
$430.84M
Beta
0.51
P/E (TTM)
-5.6
EPS (TTM)
-$1.92
52W Low $7.61High $18.31

Volume 1.67M

Average 1.21M

PHAT Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Phathom Pharmaceuticals, Inc.NASDAQ: PHAT

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q1 FY2026 research & development of $7.77M fell 15.4% year over year, behind the -7.3% change in trailing-twelve-month research & development. Sequentially, it rose 3.7% from the prior quarter. Over 3 fiscal years it compounded at -22.9% a year.

Context

  • Research & development amounted to 18.7% of revenue in FY2025, down 43.0 pp from a year earlier.
  • Research & development increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -15.4% toward the trailing-twelve-month pace of -7.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$7.77M+3.7% QoQ
Last fiscal yearDec 2025
$32.78M-3.8% YoY
LTMMar 2026
$31.37M-7.3% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-15.4%——
1 year-3.8%——
3-year CAGR-22.9%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
32.78M USD
Year-over-year change
-3.8%
4-year CAGR
-18.0%

Research & Development vs competitors

How PHAT compares with its peers on the latest reported figures

  • PHAT's LTM Mar 2026 research & development of $31.37M is the lowest of the 2 companies compared; the peer median is $74.32M.
  • Its year-over-year change of -7.3% is the lowest of 2, against a peer median of +33.9%.
  • Research & development amounts to 15.3% of revenue for PHAT, versus a peer median of 17.4%.
PHAT Competitors Peer median
Research & Development for PHAT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ARDXArdelyx, Inc.LTM Mar 2026$74.32M +33.9%+24.8%17.4%
PHATPhathom Pharmaceuticals, Inc.LTM Mar 2026$31.37M -7.3%-22.9%15.3%
Peer median (excluding PHAT) $74.32M+33.9%+24.8%17.4%

Competitors are the stored peer set for PHAT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00682K55.25M175.11M
Cost of Revenue521K620K167K7.97M22.6M
Gross Profit(521K)(620K)515K47.28M152.51M
Gross Margin——75.5%85.6%87.1%
Research & Development72.34M71.44M49.9M34.08M32.78M
Selling, General & Admin62.22M100.38M117.93M290.66M279.72M
Operating Expenses134.56M171.82M167.83M324.75M312.5M
Depreciation & Amortization521K620K575K795K633K
EBITDA(136.57M)(169.8M)(159.05M)(261.52M)(152.5M)
EBITDA Margin——-23321.0%-473.3%-87.1%
Operating Income(135.08M)(172.44M)(167.31M)(277.47M)(159.99M)
Operating Margin——-24532.6%-502.2%-91.4%
Interest Income41K2.13M7.88M15.16M7.04M
Interest Expense6.79M27.31M41.97M72.01M68.12M
Other Income / Expenses(8.8M)(25.28M)(34.28M)(56.86M)(61.26M)
Income Before Tax(143.88M)(197.72M)(201.59M)(334.33M)(221.25M)
Pre-Tax Margin——-29558.9%-605.1%-126.3%
Income Tax Expense00000
Net Income(143.88M)(197.72M)(201.59M)(334.33M)(221.25M)
Net Margin——-29558.9%-605.1%-126.3%
EPS (Basic)(4.00)(5.70)(3.93)(5.29)(3.03)
EPS (Diluted)(4.00)(5.70)(3.93)(5.29)(3.03)
Weighted Avg Shares37M39.12M51.29M63.18M72.92M
Weighted Avg Shares (Diluted)37M39.12M51.29M63.18M72.92M

Phathom Pharmaceuticals, Inc.

NASDAQ:PHAT

Intrinsic Alpha fair value

Locked

Current Price

$5.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.